FRM
CHRS icon

Fox Run Management’s Coherus Oncology CHRS Stock Holding History

Fox Run Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-17,790
Closed -$66.5K – 752
2023
Q3 		$66.5K Buy
+17,790
New +$82.2K 0.02% 649
2018
Q4 		– Sell
-12,490
Closed -$206K – 535
2018
Q3 		$206K Sell
12,490
-6,509
-34% -$115K 0.09% 472
2018
Q2 		$266K Buy
+18,999
New +$272K 0.08% 482
2018
Q1 		– Sell
-25,950
Closed -$228K – 734
2017
Q4 		$228K Buy
+25,950
New +$278K 0.07% 542
2017
Q1 		– Sell
-22,000
Closed -$619K – 586
2016
Q4 		$619K Buy
22,000
+13,600
+162% +$381K 0.33% 66
2016
Q3 		$225K Buy
+8,400
New +$229K 0.13% 364

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fox Run Management's CHRS Position: Q4 2023 in Review

Fox Run Management sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 17,790 shares — an estimated $66.5K sold.

Fox Run Management first reported a position in CHRS in Q3 2016 and held it in 6 quarters. The position peaked at $619K in Q4 2016. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Fox Run Management reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Fox Run Management sold 17,790 Coherus Oncology shares in Q4 2023, an estimated $66.5K.
  • Fox Run Management first reported a position in Coherus Oncology in Q3 2016 and held it in 6 quarters.
  • Fox Run Management's Coherus Oncology position peaked at $619K in Q4 2016.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Fox Run Management's 13F filing for Q4 2023, filed 13 Feb 2024.